Predicting stable treatment response in patients with major depression treated with hypericum extract WS® 5570/5572

Pharmacopsychiatry

Volumn 38, Issue 5, 2005, Pages 194-200

  Kieser, M ^a   Szegedi, A ^b  

^a DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERICUM EXTRACT; WS 5570; WS 5572; WS 5573;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; CONFIDENCE INTERVALS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERICUM; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PLANT EXTRACTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 26244457619     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-873153     Document Type: Article

References (40)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-IV. Washington, DC: American Psychiatric Association, 2000
2. Barnes J, Anderson LA, Phillipson JD. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583-600
3. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61: 656-663
4. Charney DS, Berman RM, Miller HL. Treatment of depression. In Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press Textbook of Psychopharmacology; 2nd ed Washington, DC: American Psychiatric Press, 1998
5. Franke L, Schewe H-J, Uebelhack R, Müller-Oerlinghausen B. Predictors of therapeutic effects in amitriptyline treatment. 1. Plasma drug levels. Pharmacopsychiatry 2003; 36: 134-142
6. Franklin M, Cowen PJ. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man. Pharmacopsychiatry 2001; 34 (1, suppl): S29-37
7. Glass RM. Depression: a call for papers. JAMA 2002; 288: 1400-1401
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296
9. Harrison P. Herbal medicine takes root in Germany. CMAJ 1998; 158: 637-639
10. Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry 2001; 34: 96-103
11. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry 2001; 34 (1, suppl): S51-55
12. Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187: 532-538
13. Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Phytomedicine 1998; 5: 435-442
14. Laakmann G, Jahn G, Schüle C. Hypericum-perforatum-Extrakt bei der Behandlung leichter bis mittelschwerer Depressionen. Klinische und pharmakologische Aspekte. Nervenarzt 2002; 73: 600-612
15. Laakmann G, Schüle C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31 (1, suppl): 545-549
16. Lecrubier Y. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Eur Neuropsychopharmacol 2001; 11 (3, suppl): 105-106
17. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's Wort Extract WS 5570 in Major Depression: A Double-Blind, Placebo-Controlled Trial. Am J Psychiatry 2002; 159: 1361-1366
18. Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 2001; 62 (4, suppl): 12-16; discussion 37-40
19. Leon AC, Blier P, Culpepper L, Gorman JM, Hirschfeld RM, Nierenberg AA et al. An ideal trial to test differential onset of antidepressant effect. J Clin Psychiatry 2001; 62 (4, suppl): 34-36; discussion 37-40
20. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-258
21. Möller HK, Müller H, Volz HP. How to assess the onset of antidepressant effect: Comparison of global ratings and findings based on depression scales. Pharmacopsychiatry 1996; 29: 57-62
22. Montgomery SA. Are 2-week trials sufficient to indicate efficacy? Psychopharmacol Bull 1995; 31: 41-44
23. Müller WE, Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry 1997; 30 (2, suppl): 71
24. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the EDCEU Assessment Battery Chevy Chase, Md: U.S. National Institute of Mental Health, Psychopharmacol Res Branch, 1976; 12: 12-16
25. Norman C, Hörn M, Hummel B, Grunze H, Walden J. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 2004; 37: 123-126
26. Quitkin FM, McGrath PJ, Stewart JW, Taylor BP, Klein DF. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology 1996; 15: 390-394
27. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, Mc Grath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 1987; 44: 259-264
28. Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepec-Welikson K, Tricamo E et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993; 150: 566-570
29. Quitkin FM, Stewart JW, McGrath PJ, Taylor B, Beasley C, Stewart J et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry 2002; 159: 1848-1854
30. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol 2002; 438: 117-128
31. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001; 62 (4, suppl): 17-23; discussion 37-40
32. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996; 29: 87-96
33. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999; 32: 56-60
34. Stassen HH, Dahmen N, Giegling I, Nürnberg P, Rujescu D, Sander T, Toliat MR, Szegedi A. Genetic predisposition to psychotropic drug response. Poster presentation at ZNZ Symposium 2003, Zurich (17. October 2003).
35. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3: 127-135
36. Stassen HH, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacol 1998; 8: 303-310
37. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003; 64: 413-420
38. Tedlow J, Fava M, Uebelacker L, Nierenberg NN, Alpert JE, Rosenbaum J. Outcome definitions and predictors in depression. Psychother Psychosom 1998; 67: 266-270
39. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry 1997; 30 (2, suppl): 72-76
40. Wheatley D. Hypericum extract. Potential in the treatment of depression. CNS Drugs 1998; 9: 431-440